Pressmeddelanden

Lipigon Pharmaceuticals announces collaboration with Singapore lung health initiative TARIPH and Shenzhen Institutes of Advanced Technology to study a potential novel treatment for COVID-19

Lipigon Pharmaceuticals AB ("Lipigon"), today announced that the company has entered into a collaboration agreement with The Academic Respiratory Initiative for Pulmonary Health (TARIPH) at Nanyang Technological University, Singapore ("NTU Singapore") and Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (SIAT). The parties will collaborate on a potential novel treatment for Acute Respiratory Distress Syndrome (ARDS), a common and lethal co-morbidity of pneumonia caused by SARS-CoV-2 pandemic and other infectious lung disorders.

"This is a strategically important collaboration that allows Lipigon to test its drug candidates for potential use in treatment in Covid-19 and other infectious lung diseases. It is a great opportunity for us to work with leading experts in this area" explains CEO and co-founder Dr. Stefan K Nilsson.

Lipigon,TARIPH and SIAT will collaborate in the validation of antisense oligonucleotide (ASO) drug candidates targeting angiopoietin-like 4 (ANGPTL4). As part of TARIPH, Associate Professor Nguan Soon Tan's research group at NTU's Lee Kong Chian School of Medicine has shown in several publications that ANGPTL4 plays an important role in lung injury, as it was among the most significantly upregulated genes in the 1918 Spanish flu and 2009 H1N1 swine flu pandemics.

Lipigon has developed ASO drug candidates targeting ANGPTL4 that potentially could treat patients suffering from inflammation-associated lung injury including ARDS. These compounds will be tested by Professor Tan and collaborators, in advanced disease models to provide proof-of-concept for this novel treatment. The compounds have been optimized for efficacy and safety by Lipigon. If proven efficient for treating ARDS these compounds could immediately enter non-clinical safety trials.

"Professor Tan's outstanding research on pulmonary vasculature leakiness and pathological angiogenesis has established ANGPTL4 as a promising drug target. We are extremely happy and fortunate to enter this collaboration which gives our compounds a fast-track to proof of concept in relevant disease models", said Dr. Stefan K. Nilsson. "The SAR-CoV-2 pandemic has pinpointed a significant medical need for novel treatments of all infectious lung diseases. We believe that ANGPTL4 inhibition could make a difference for millions of patients every year".

"Over the last decade, our laboratory findings have suggested that when the expression of ANGPTL4 is suppressed, the duration and severity of lung damage is also reduced, suggesting a strong possibility for faster recovery. I hope our collaboration will lead to significant clinical benefit to patients suffering from lung injury caused by severe pneumonia," said Associate Professor Nguan Soon Tan.

"Our research on ANGPTL4 function in acute lung injury showed potential of ANGPTL4 as a broadspectrum therapy target for pneumonia. We hope our collaboration can provide new tools for clinicians," said Associate Professor Liang Li.

To accelerate the preclinical validation of ANGPTL4 ASO for lung injury, research will be carried out by Professor Tan and his colleagues, including Provost's Chair in Molecular Medicine Assistant Professor Sanjay Chotirmall and Dr Louisa Chan from LKCMedicine, as well as Associate Professor Li Liang from Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.

 

Press Release September 22nd, 2020

For further information, please contact:

Stefan K Nilsson, CEO Lipigon

Mobile +46 70-578 17 68

Mail: stefan@lipigon.se

www.lipigon.se

About ANGPTL4 and ARDS

Pneumonia kill millions of individuals, most commonly from severe inflammatory response causing damages to the lungs. ANGPTL4 is a gene associated with acute lung injury in both viral and bacterial pneumonia; mainly by promoting pathological angiogenesis and vascular leakage. Infectious lung disease may lead to acute respiratory distress syndrome (ARDS) which is a life-threatening syndrome characterized by acute inflammation in combination with respiratory failure. Patients are commonly treated with oxygen and often mechanical ventilation at intensive care units. Treatment of the infection that causes pneumonia is sometimes not possible, as in the case of SARS-CoV-2 infection and COVID-19, thus there is a great unmet medical need for novel ARDS treatments.

About Lipigon Pharmaceuticals AB

Lipigon develops novel therapeutics for patients with lipid-related disorders. The company is a spin-off from Umeå University, Sweden, based on five decades of lipid research. Our primary focus is orphan lipid disorders and in addition to the ANGPTL antisense program, Lipigon's pipeline includes a program for gene therapy in lipodystrophy, together with Combigene AB (publ) and a small molecule program in collaboration with HitGen (Inc). 

2021-04-30
Regulatorisk

Lipigon Pharmaceuticals AB publicerar bolagets årsredovisning för räkenskapsåret 2020.

2021-04-26
Regulatorisk

Aktieägarna i Lipigon Pharmaceuticals AB, org.nr 556810-9077, ("Bolaget") kallas härmed till årsstämma den 26 maj 2021 kl. 15.00 i Bolagets lokaler på Tvistevägen 48C i Umeå.

2021-03-17

Lipider, eller fetter i vardagligt tal, har en livsviktiga funktioner i kroppen men i fel mängd och på fel plats kan de orsaka allvarliga sjukdomar. Lär dig mer om blodfetter och blodfettsrubbningar med läkemedelsbolaget Lipigon.

I en artikelserie möter vi några av Lipigons nyckelpersoner som berättar om arbetet med att utveckla läkemedel för sjukdomar som orsakas av störningar i fettomsättningen. Först ut är Gunilla Olivecrona, medgrundare och seniorprofessor vid Umeå universitet, som tar oss med in i lipidernas värld och förklarar allt vi behöver veta om lipider.

Artikeln finns också att läsa här.

2021-03-10
Regulatorisk

Lipigon Pharmaceuticals AB ("Lipigon"), som utvecklar läkemedel för så kallade lipidrelaterade sjukdomar, meddelade i dag att bolaget har utökat samarbetsavtalet med HitGen Inc. ("HitGen"), som är noterat på Shanghai-börsen, med ytterligare ett målprotein. Målsättningen är att gemensamt utveckla en behandling för kardiometabola sjukdomar.

2021-03-10
Regulatory

Lipigon Pharmaceuticals AB ("Lipigon"), developer of therapeutics for lipid-related diseases, today announced that the company has expanded its agreement with the Shanghai STAR listed company HitGen Inc. ("HitGen") to include a second novel target protein. With joint efforts, the aim is to develop a treatment for cardiometabolic disease.

2021-03-04

Stefan K. Nilsson, VD för nyligen börsintroducerade Lipigon kommer att presentera bolaget på Aktieportföljen Live på onsdag den 10 mars klockan 20.30-20.55. Eventet genomförs digitalt. Varmt välkommen.

2021-03-01
Regulatorisk

I dag, den 1 mars 2021, inleds handeln i Lipigon Pharmaceuticals AB:s ("Lipigon" eller "Bolaget") aktier och teckningsoptioner på Nasdaq First North Growth Market. Lipigons aktie handlas under kortnamnet "LPGO" med ISIN-kod SE00015382072. Teckningsoption handlas under kortnamnet "LPGO TO1" med ISIN-kod SE0015482765.

2021-02-25

Pressmeddelande publicerat kl. 09:57 i dag den 25 januari 2021 innehöll fel kortnamn för teckningsoptionen. Korrekt kortnamn ska vara "LPGO TO1", vilket har justerats i pressmeddelandet som återfinns i sin helhet nedan.

Lipigon Pharmaceuticals AB ("Lipigon" eller "Bolaget") har ansökt om och erhållit sedvanligt villkorat godkännande för upptagande till handel på Nasdaq First North Growth Market. Första dag för handel är måndag den 1 mars 2021.

2021-02-25

Lipigon Pharmaceuticals AB ("Lipigon" eller "Bolaget") har ansökt om och erhållit sedvanligt villkorat godkännande för upptagande till handel på Nasdaq First North Growth Market. Första dag för handel är måndag den 1 mars 2021.

2021-02-15

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SINGAPORE, SYDAFRIKA, USA ELLER NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING SKULLE VARA OTILLÅTEN ELLER KRÄVA REGISTRERING ELLER ANNAN ÅTGÄRD ENLIGT TILLÄMPLIG LAG.

1
2
3
4
5

Nyheter

30 april, 2021, Pressmeddelande

Lipigon publicerar årsredovisning för 2020

Lipigon Pharmaceuticals AB publicerar bolagets årsredovisning för räkenskapsåret 2020.

26 april, 2021, Pressmeddelande

Kallelse till årsstämma i Lipigon Pharmaceuticals AB

Aktieägarna i Lipigon Pharmaceuticals AB, org.nr 556810-9077, ("Bolaget") kallas härmed till årsstäm...

17 mars, 2021, Pressmeddelande

Vad är lipider och varför spelar de en sådan viktig roll för hälsan?

Lipider, eller fetter i vardagligt tal, har en livsviktiga funktioner i kroppen men i fel mängd och ...